Streetbeat News

Marketing

WMT

A Walmart spokesperson stated that the company is not advertising on platform X, having found alternative platforms that more effectively reach their customer base.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 5:12 pm

AAPL

AMZN

GLD

GOOG

META

MSFT

NVDA

QQQ

SLV

SPY

TLT

TSLA

USO

The stock market experienced its second-best November since the 1980s, largely due to rising bond prices as indicated by the iShares 20 Plus Year Treasury Bond ETF (TLT), and amplified by market mechanics. Investors are advised to watch for a potential break above the lower resistance zone in bonds, which could trigger another stock market rally. Jerome Powell's speech in Atlanta is anticipated, with the market looking for indications on interest rate cuts. If Powell supports the market's rate cut projections, a significant rally is expected; if he contradicts them, a pullback is likely. Early trade money flows are negative for major tech stocks and ETFs like SPY and QQQ. The momo crowd is buying stocks and gold, while smart money activity is undisclosed. Oil trading is volatile due to OPEC+ uncertainties, and Bitcoin is showing a positive bias, potentially aiming to break above $40,000.

Portfolio Pulse from The Arora Report

December 01, 2023 | 4:37 pm

CANC

HRTS

LUX

MSFT

ROYA

RSHO

TOLL

Tema ETFs is revolutionizing thematic investing by focusing on long-term structural trends and precise security selection, avoiding short-term market fads. Yuri Khodjamirian, CFA, highlighted Tema's approach during Benzinga's 'ETFs Unlocked' session. Tema ETFs, with six funds in the market, emphasizes quality and alignment between themes and securities, as seen in their ETFs targeting reshoring in the U.S. (RSHO), cardio-metabolic diseases (HRTS), and luxury goods (LUX). The company also offers ETFs focused on oncology (CANC), global royalties (ROYA), and monopolies and oligopolies (TOLL).

Portfolio Pulse from Piero Cingari

December 01, 2023 | 4:14 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo provides daily trading strategies for SPY, QQQ, AAPL, MSFT, TSLA, META, GOOGL, and NVDA, based on a proprietary formula considering price, volume, and options flow. The memo outlines potential support and resistance levels for each asset, suggesting possible targets for bullish and bearish scenarios. The market is expected to show volatility in response to PMI data and Jerome Powell's speech, with the FOMC rate decision approaching. The memo is part of a service offering by RIPS, a professional trader, who provides insights and real-time mentorship to Market Clubhouse members.

Portfolio Pulse from RIPS

December 01, 2023 | 3:35 pm

FRHC

Freedom Holding Corp. has been approved to implement a strategic plan to enter the telecommunications market in Kazakhstan, aiming to expand its business operations.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 3:20 pm

TTWO

Rockstar Games has announced the release of 'Trailer 1' on Tuesday, December 5 at 9AM ET. The announcement was made via a tweet, which could indicate an upcoming game or significant update. This news may generate excitement and anticipation among gamers and investors.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 2:27 pm

JAZZ

Jazz Pharmaceuticals (NASDAQ:JAZZ) will present data from nine abstracts at the 2023 American Epilepsy Society Annual Meeting, emphasizing its commitment to treatment-resistant epilepsy. The presentations will include real-world outcomes of Epidiolex (cannabidiol) in treatment-resistant focal epilepsies and data on caregiver-reported outcomes in patients with tuberous sclerosis complex (TSC) prescribed Epidiolex. The data suggests sustained reduction in focal-onset seizures and improvements in cognition, emotional functioning, and communication in patients. The Expanded Access Program (EAP) and GWPCARE6 Open-Label Extension (OLE) trial results will also be shared.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 2:09 pm

FOXO

FOXO Technologies Inc. (NYSE:FOXO) is set to begin the commercial rollout of its VITHAR AI Health Coach in early 2024. The company anticipates a reduction in losses exceeding $10 million for Q3 2023 compared to the previous quarter, including operational cost savings of over $2.1 million. Interim CEO Mark White highlighted progress in the VITHAR rollout and plans to use KR8's social media network for marketing. FOXO expects to report annualized cost savings of over 52% for 2023 and aims to maintain a lean operating structure to scale the business and drive profitability post-launch.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 2:08 pm

NVTS

Navitas Semiconductor (NASDAQ:NVTS) is showcasing its GaNFast gallium nitride and GeneSiC silicon carbide power semiconductors at the 'Bodo's WBG Event' in Munich. As a leader in wide bandgap (WBG) semiconductors, Navitas has shipped over 100 million GaN and 12 million SiC power devices. The company will present its latest technologies aimed at markets such as EV, solar, energy storage, and AI data centers. The event features discussions on the adoption of SiC and GaN materials, and presentations on the advantages of Navitas' power ICs and GeneSiC MOSFETs.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:32 pm

WGS

GeneDx (NASDAQ:WGS) announced new data supporting exome sequencing over multi-gene panels for epilepsy diagnosis, to be presented at the AES annual meeting. The study of 22,500 individuals showed a 25% diagnosis rate with exome sequencing, higher than the 19% with multi-gene panels. 78% of those diagnosed had prior testing, indicating exome sequencing's superior diagnostic ability. Over half of seizure-related genes are not on many epilepsy panels. 11% of positive diagnoses from exome sequencing involved treatment-related genes. GeneDx will also present data on better insurance coverage for exome sequencing. The NSGC and AES recommend exome sequencing as a first-tier test for unexplained epilepsy. GeneDx will host a symposium at the conference discussing the benefits of exome sequencing for epilepsy patients.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:31 pm